IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) Fundamental Analysis & Valuation

BIT:1IOVA • US4622601007

Current stock price

4.4535 EUR
+0.98 (+28.38%)
Last:

This 1IOVA.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. 1IOVA.MI Profitability Analysis

1.1 Basic Checks

  • In the past year 1IOVA has reported negative net income.
  • In the past year 1IOVA has reported a negative cash flow from operations.
  • In the past 5 years 1IOVA always reported negative net income.
  • In the past 5 years 1IOVA always reported negative operating cash flow.
1IOVA.MI Yearly Net Income VS EBIT VS OCF VS FCF1IOVA.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M -400M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -42.82%, 1IOVA is doing worse than 60.49% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -55.97%, 1IOVA is in line with its industry, outperforming 59.26% of the companies in the same industry.
Industry RankSector Rank
ROA -42.82%
ROE -55.97%
ROIC N/A
ROA(3y)-46.87%
ROA(5y)-48.85%
ROE(3y)-61.44%
ROE(5y)-63.72%
ROIC(3y)N/A
ROIC(5y)N/A
1IOVA.MI Yearly ROA, ROE, ROIC1IOVA.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • 1IOVA has a Gross Margin (28.66%) which is in line with its industry peers.
  • 1IOVA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 28.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
1IOVA.MI Yearly Profit, Operating, Gross Margins1IOVA.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. 1IOVA.MI Health Analysis

2.1 Basic Checks

  • 1IOVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • 1IOVA has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for 1IOVA has been increased compared to 5 years ago.
  • 1IOVA has a better debt/assets ratio than last year.
1IOVA.MI Yearly Shares Outstanding1IOVA.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
1IOVA.MI Yearly Total Debt VS Total Assets1IOVA.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of 0.92, we must say that 1IOVA is in the distress zone and has some risk of bankruptcy.
  • 1IOVA's Altman-Z score of 0.92 is in line compared to the rest of the industry. 1IOVA outperforms 55.56% of its industry peers.
  • 1IOVA has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.00, 1IOVA belongs to the top of the industry, outperforming 96.30% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.92
ROIC/WACCN/A
WACC9.03%
1IOVA.MI Yearly LT Debt VS Equity VS FCF1IOVA.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 3.20 indicates that 1IOVA has no problem at all paying its short term obligations.
  • The Current ratio of 1IOVA (3.20) is better than 67.90% of its industry peers.
  • A Quick Ratio of 2.83 indicates that 1IOVA has no problem at all paying its short term obligations.
  • The Quick ratio of 1IOVA (2.83) is better than 62.96% of its industry peers.
Industry RankSector Rank
Current Ratio 3.2
Quick Ratio 2.83
1IOVA.MI Yearly Current Assets VS Current Liabilites1IOVA.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. 1IOVA.MI Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 13.85% over the past year.
  • The Revenue has grown by 60.60% in the past year. This is a very strong growth!
EPS 1Y (TTM)13.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.77%
Revenue 1Y (TTM)60.6%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%17.74%

3.2 Future

  • 1IOVA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.21% yearly.
  • 1IOVA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.64% yearly.
EPS Next Y54.18%
EPS Next 2Y34.08%
EPS Next 3Y27.13%
EPS Next 5Y20.21%
Revenue Next Year52.08%
Revenue Next 2Y44.63%
Revenue Next 3Y41.58%
Revenue Next 5Y27.64%

3.3 Evolution

1IOVA.MI Yearly Revenue VS Estimates1IOVA.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
1IOVA.MI Yearly EPS VS Estimates1IOVA.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. 1IOVA.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for 1IOVA. In the last year negative earnings were reported.
  • Also next year 1IOVA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
1IOVA.MI Price Earnings VS Forward Price Earnings1IOVA.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
1IOVA.MI Per share data1IOVA.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

  • 1IOVA's earnings are expected to grow with 27.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.08%
EPS Next 3Y27.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. 1IOVA.MI Dividend Analysis

5.1 Amount

  • No dividends for 1IOVA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

1IOVA.MI Fundamentals: All Metrics, Ratios and Statistics

IOVANCE BIOTHERAPEUTICS INC

BIT:1IOVA (3/10/2026, 7:00:00 PM)

4.4535

+0.98 (+28.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24
Earnings (Next)05-06
Inst Owners64.07%
Inst Owner ChangeN/A
Ins Owners0.33%
Ins Owner ChangeN/A
Market Cap1.83B
Revenue(TTM)263.50M
Net Income(TTM)-390.98M
Analysts78.82
Price Target7.88 (76.94%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.11%
Min EPS beat(2)-2.78%
Max EPS beat(2)5%
EPS beat(4)1
Avg EPS beat(4)-14.73%
Min EPS beat(4)-47.45%
Max EPS beat(4)5%
EPS beat(8)5
Avg EPS beat(8)-4.74%
EPS beat(12)8
Avg EPS beat(12)3.08%
EPS beat(16)11
Avg EPS beat(16)3.15%
Revenue beat(2)1
Avg Revenue beat(2)-1.63%
Min Revenue beat(2)-8.66%
Max Revenue beat(2)5.4%
Revenue beat(4)1
Avg Revenue beat(4)-14.96%
Min Revenue beat(4)-40.82%
Max Revenue beat(4)5.4%
Revenue beat(8)3
Avg Revenue beat(8)-11.95%
Revenue beat(12)3
Avg Revenue beat(12)-37%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.85%
PT rev (3m)22.29%
EPS NQ rev (1m)11.26%
EPS NQ rev (3m)12.02%
EPS NY rev (1m)13.54%
EPS NY rev (3m)20.42%
Revenue NQ rev (1m)1.6%
Revenue NQ rev (3m)1.6%
Revenue NY rev (1m)-5.06%
Revenue NY rev (3m)-7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.05
P/FCF N/A
P/OCF N/A
P/B 3.03
P/tB 5.06
EV/EBITDA N/A
EPS(TTM)-0.97
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS0.55
BVpS1.47
TBVpS0.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.82%
ROE -55.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 28.66%
FCFM N/A
ROA(3y)-46.87%
ROA(5y)-48.85%
ROE(3y)-61.44%
ROE(5y)-63.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 94.15%
Cap/Sales 12.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.2
Quick Ratio 2.83
Altman-Z 0.92
F-Score4
WACC9.03%
ROIC/WACCN/A
Cap/Depr(3y)77.2%
Cap/Depr(5y)331.82%
Cap/Sales(3y)631.42%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.77%
EPS Next Y54.18%
EPS Next 2Y34.08%
EPS Next 3Y27.13%
EPS Next 5Y20.21%
Revenue 1Y (TTM)60.6%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%17.74%
Revenue Next Year52.08%
Revenue Next 2Y44.63%
Revenue Next 3Y41.58%
Revenue Next 5Y27.64%
EBIT growth 1Y-2.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.83%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.33%
OCF growth 3YN/A
OCF growth 5YN/A

IOVANCE BIOTHERAPEUTICS INC / 1IOVA.MI Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for IOVANCE BIOTHERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to 1IOVA.MI.


What is the valuation status of IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) stock?

ChartMill assigns a valuation rating of 1 / 10 to IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI). This can be considered as Overvalued.


Can you provide the profitability details for IOVANCE BIOTHERAPEUTICS INC?

IOVANCE BIOTHERAPEUTICS INC (1IOVA.MI) has a profitability rating of 1 / 10.